Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Faeth Therapeutics, Inc.
NASDAQ:FTH
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Tango Therapeutics, Inc. NASDAQ:TNGX | $4.32B | $25.50 | Not rated | -38.9 | +173.63% |
Relay Therapeutics, Inc. NASDAQ:RLAY | $4.00B | $18.09 | Not rated | -10.5 | +153.61% |
Nuvation Bio Inc. NYSE:NUVB | $1.40B | $3.99 | Not rated | -12.8 | -21.25% |
Verastem, Inc. NASDAQ:VSTM | $1.03B | $8.18 | Not rated | -2.1 | -25.89% |
Kura Oncology, Inc. NASDAQ:KURA | $713.90M | $7.77 | Not rated | -2.9 | -33.75% |
Janux Therapeutics, Inc. NASDAQ:JANX | $695.66M | $11.37 | Not rated | -7.6 | -64.47% |
Puma Biotechnology, Inc. NASDAQ:PBYI | $401.70M | $7.77 | Overvalued | 15.4 | +42.69% |
Prelude Therapeutics Incorporated NASDAQ:PRLD | $275.32M | $3.45 | Not rated | -4.5 | +96.43% |
Boundless Bio, Inc. NASDAQ:BOLD | $59.03M | $2.50 | Not rated | -1.0 | +101.68% |
Continue the stock analysis
Jump to another research area for this company.